Does Sarcopenia Impact Complications and Overall Survival in Patients Undergoing Radical Nephrectomy for Stage III and IV Kidney Cancer?

Cc, Peyton; Mg, Heavner; Jt, Rague; Ls, Krane; Höhn, Anne Kathrin

doi:10.1089/end.2015.0492

Cited by 55 publications

(50 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although in some studies a correlation between PA and post‐operative complications was seen, the majority have failed to prove a relationship between PA‐assessed sarcopenia and survival 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23. Only few have actually assessed the agreement between PA and SMA within their population; Jones et al studied 100 patients with colorectal cancer and reported a Spearman correlation of 0.8 for PA and SMA and a Spearman correlation of 0.94 for PA and PLW, which could not be reproduced in our cohort 11.…”

Section: Discussionmentioning

confidence: 99%

“…This method has been used to predict surgical complications in different cancer types with contrasting results. PA has shown a correlation with post‐operative complications in individual studies on colorectal cancer, colorectal liver metastases, kidney cancer, bladder cancer, cholangiocarcinoma, and hepatocellular cancer,11, 12, 13, 14, 15, 16 while this effect was not seen in other pancreatic cancer, endometrial cancer, biliary cancer, or sarcoma studies 17, 18, 19, 20. Interestingly, only few cancer studies were able to show a correlation between PA and survival 21, 22, 23.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer

Rutten

Ubachs

Kruitwagen

et al. 2017

J cachexia sarcopenia muscle

150

130

View full text Add to dashboard Cite

BackgroundComputed tomography measurements of total skeletal muscle area can detect changes and predict overall survival (OS) in patients with advanced ovarian cancer. This study investigates whether assessment of psoas muscle area reflects total muscle area and can be used to assess sarcopenia in ovarian cancer patients.MethodsOvarian cancer patients (n = 150) treated with induction chemotherapy and interval debulking were enrolled retrospectively in this longitudinal study. Muscle was measured cross sectionally with computed tomography in three ways: (i) software quantification of total skeletal muscle area (SMA); (ii) software quantification of psoas muscle area (PA); and (iii) manual measurement of length and width of the psoas muscle to derive the psoas surface area (PLW). Pearson correlation between the different methods was studied. Patients were divided into two groups based on the extent of change in muscle area, and agreement was measured with kappa coefficients. Cox‐regression was used to test predictors for OS.ResultsCorrelation between SMA and both psoas muscle area measurements was poor (r = 0.52 and 0.39 for PA and PLW, respectively). After categorizing patients into muscle loss or gain, kappa agreement was also poor for all comparisons (all κ < 0.40). In regression analysis, SMA loss was predictive of poor OS (hazard ratio 1.698 (95%CI 1.038–2.778), P = 0.035). No relationship with OS was seen for PA or PLW loss.ConclusionsChange in psoas muscle area is not representative of total muscle area change and should not be used to substitute total skeletal muscle to predict survival in patients with ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer

Rutten

Ubachs

Kruitwagen

et al. 2017

J cachexia sarcopenia muscle

150

130

View full text Add to dashboard Cite

show abstract

“…1 To date several studies have demonstrated adverse outcomes following abdominal surgery to be associated with sarcopaenia indicating a potential role in patient risk stratification. [2][3][4][5][6][7] The two dominant methods used to radiologically quantify sarcopaenia include the measurement of the total psoas muscle area (TPMA) or total abdominal muscle area, which typically includes the: psoas, erector spinae, quadratus lumborum, transversus abdominis, external and internal oblique's, and rectus abdominis muscles. Measurements are universally made from single slice imaging at the level of the third lumbar vertebrae or umbilicus.…”

Section: Introductionmentioning

confidence: 99%

Influences of clinical experience in the quantification of morphometric sarcopaenia: a cohort study

Waduud

Drozd

Linton

et al. 2018

BJR

View full text Add to dashboard Cite

“…(continued)Peyton et al (2015) [99] 128 L3 lowest quartile TPA/height 2 in cm 2 /m 2 Renal cancer HU: 220 to 1100 Males: #4.27 Females: #3.80Muscle mass associated with major postoperative complications instead of mortality. Abbreviations: BMI, body mass index; DLBCL, diffuse large B-cell lymphoma; HU, Hounsfield unit; L3, lumbar vertebra 3; TAMA, total abdominal muscle area; TPA, total psoas area (psoas muscle area only).…”

mentioning

confidence: 99%

The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature

et al. 2016

View full text Add to dashboard Cite

In several diseases, low muscle mass has been revealed as an unfavorable prognostic factor for outcome.Whether this holds true in patients with solid malignancies as well has increasingly been explored recently. However, this research field is severely hampered by a lack of consensus on how to determine muscle mass in cancer patients and on the definition of low muscle mass. Consequently, the prevalence of low muscle mass varies widely across several studies. Nevertheless, most studies show that, in patients with solid malignancies, low muscle mass is associated with a poor outcome. In the future, more research is needed to get better insight into the best method to determine muscle mass, the exact prognostic value of low muscle mass in diverse tumor types and stages, pathophysiology of low muscle mass in patients with cancer, and ways to intervene and improve muscle mass in patients. This review addresses the current literature on the importance of muscle mass in cancer patients and the methods of muscle measurement. The Oncologist 2016;21:1396-1409 Implications for Practice: An increasing number of studies underline the clinical value of low muscle mass as a prognostic factor for adverse outcomes in cancer patients. However, studies show large heterogeneity because of the lack of a standardized approach to measure muscle mass and the lackof reference populations. As a result, the interpretation of data and further progress are severely hampered, hindering the implementation of muscle measurement in oncological care. This review summarizes the methods of diagnosing low muscle mass in cancer patients, the difference between underlying syndromes such as sarcopenia and cachexia, and the association with clinical outcomes described so far.

show abstract

Does Sarcopenia Impact Complications and Overall Survival in Patients Undergoing Radical Nephrectomy for Stage III and IV Kidney Cancer?

Abstract: Sarcopenia appears to be associated with risk of major complication after radical nephrectomy for advanced kidney cancer. It was not related to overall survival, however. This preoperative imaging tool may be helpful in preoperative counseling and preparation.

Cited by 55 publications

References 30 publications

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer

Influences of clinical experience in the quantification of morphometric sarcopaenia: a cohort study

The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature

Contact Info

Product

Resources

About